Unit
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
[Elective splenectomy in adults - preparation, operation, and postoperative treatment]
Worni M, Schudel H, Gueller U. [Elective splenectomy in adults - preparation, operation, and postoperative treatment]. Ther Umsch 2013; 70:171-6.
Mar 1, 2013[Elective splenectomy in adults - preparation, operation, and postoperative treatment]
Mar 1, 2013Ther Umsch 2013; 70:171-6
Worni Mathias, Schudel Hans H, Gueller Ulrich
Haematopoietic stem cell transplantation: activity in Switzerland compared with surrounding European countries
Passweg J, Schanz U, Stussi G, Stern M, Renner C, Pabst T, Ozsahin H, de Faveri G, Leibundgut K, Hess U, Güngör T, Gratwohl A, Duchosal M, Chalandon Y, Bucher C, Bargetzi M, Baldomero H, SBST (Swiss Blood Stem Cell Transplantation Group). Haematopoietic stem cell transplantation: activity in Switzerland compared with surrounding European countries. Swiss Med Wkly 2013; 143:w13757.
Feb 22, 2013Haematopoietic stem cell transplantation: activity in Switzerland compared with surrounding European countries
Feb 22, 2013Swiss Med Wkly 2013; 143:w13757
Passweg Jakob R, Schanz Urs, Stussi Georg, Stern Martin, Renner Christoph, Pabst Thomas, Ozsahin Hulya, de Faveri Grazia Nicoloso, Leibundgut Kurt, Hess Urs, Güngör Tayfun, Gratwohl Alois, Duchosal Michel A, Chalandon Yves, Bucher Christoph, Bargetzi Mario, Baldomero Helen, SBST (Swiss Blood Stem Cell Transplantation Group)
Influence of a nutritional intervention on dietary intake and quality of life in cancer patients: a randomized controlled trial
Uster A, Ruefenacht U, Ruehlin M, Pless M, Siano M, Haefner M, Imoberdorf R, Ballmer P. Influence of a nutritional intervention on dietary intake and quality of life in cancer patients: a randomized controlled trial. Nutrition 2013; 29:1342-9.
Feb 19, 2013Influence of a nutritional intervention on dietary intake and quality of life in cancer patients: a randomized controlled trial
Feb 19, 2013Nutrition 2013; 29:1342-9
Uster Alexandra, Ruefenacht Ursula, Ruehlin Maya, Pless Miklos, Siano Marco, Haefner Mark, Imoberdorf Reinhard, Ballmer Peter E
Interdiziplinäre Therapie der Extremitäten Weichteil-Sarkome
Keller S, Putora P, Rothermundt C. Interdiziplinäre Therapie der Extremitäten Weichteil-Sarkome. info@onkologie 2013; 2:14-17.
Feb 14, 2013Interdiziplinäre Therapie der Extremitäten Weichteil-Sarkome
Feb 14, 2013info@onkologie 2013; 2:14-17
Keller S, Putora Paul Martin, Rothermundt Christian
Angioedema in a renal cell cancer patient treated with everolimus in combination with an ACE inhibitor
Rothermundt C, Gillessen Sommer S. Angioedema in a renal cell cancer patient treated with everolimus in combination with an ACE inhibitor. J Clin Oncol 2013; 31:e57-8.
Feb 10, 2013Angioedema in a renal cell cancer patient treated with everolimus in combination with an ACE inhibitor
Feb 10, 2013J Clin Oncol 2013; 31:e57-8
Rothermundt Christian, Gillessen Sommer Silke
Management der Von Hippel-Lindau Erkrankung
Hundsberger T. Management der Von Hippel-Lindau Erkrankung - Eine interdisziplinäre Herausforderung. info@onkologie 2013; 04:24-28.
Feb 9, 2013Management der Von Hippel-Lindau Erkrankung
Feb 9, 2013info@onkologie 2013; 04:24-28
Hundsberger Thomas
HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer
Denkert C, von Minckwitz G, Tesch H, Hansmann M, Reinisch M, Engels K, Sinn B, Fasching P, Mehta K, Solbach C, Brase J, Darb-Esfahani S, Kronenwett R, Prinzler J, Loibl S, Huober J, Untch M. HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer. Breast Cancer Res 2013; 15:R11.
Feb 7, 2013HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer
Feb 7, 2013Breast Cancer Res 2013; 15:R11
Denkert Carsten, von Minckwitz Gunter, Tesch Hans, Hansmann Martin-Leo, Reinisch Mattea, Engels Knut, Sinn Bruno V, Fasching Peter A, Mehta Keyur, Solbach Christine, Brase Jan C, Darb-Esfahani Silvia, Kronenwett Ralf, Prinzler Judith, Loibl Sibylle, Huober Jens, Untch Michael
Chemotherapy regimens in early breast cancer: major controversies and future outlook
Jörger M, Thürlimann B. Chemotherapy regimens in early breast cancer: major controversies and future outlook. Expert Rev Anticancer Ther 2013; 13:165-78.
Feb 1, 2013Chemotherapy regimens in early breast cancer: major controversies and future outlook
Feb 1, 2013Expert Rev Anticancer Ther 2013; 13:165-78
Jörger Markus, Thürlimann Beat
Leukämie muss kein Todesurteil mehr sein
Hess U. Leukämie muss kein Todesurteil mehr sein. Schweizer Zeitschrift für Onkologie 2013; 2/2013
Feb 1, 2013Leukämie muss kein Todesurteil mehr sein
Feb 1, 2013Schweizer Zeitschrift für Onkologie 2013; 2/2013
Hess Urs
High risks for adverse outcomes after gastric bypass surgery following failed gastric banding: a population-based trend analysis of the United States
Worni M, Østbye T, Shah A, Carvalho E, Schudel I, Shin J, Pietrobon R, Gueller U. High risks for adverse outcomes after gastric bypass surgery following failed gastric banding: a population-based trend analysis of the United States. Ann Surg 2013; 257:279-86.
Feb 1, 2013High risks for adverse outcomes after gastric bypass surgery following failed gastric banding: a population-based trend analysis of the United States
Feb 1, 2013Ann Surg 2013; 257:279-86
Worni Mathias, Østbye Truls, Shah Anand, Carvalho Elias, Schudel Inge M, Shin Jin Hee, Pietrobon Ricardo, Gueller Ulrich
Racial differences among patients undergoing laparoscopic gastric bypass surgery: a population-based trend analysis from 2002 to 2008
Worni M, Gueller U, Maciejewski M, Curtis L, Gandhi M, Pietrobon R, Jacobs D, Ostbye T. Racial differences among patients undergoing laparoscopic gastric bypass surgery: a population-based trend analysis from 2002 to 2008. Obes Surg 2013; 23:226-33.
Feb 1, 2013Racial differences among patients undergoing laparoscopic gastric bypass surgery: a population-based trend analysis from 2002 to 2008
Feb 1, 2013Obes Surg 2013; 23:226-33
Worni Mathias, Gueller Ulrich, Maciejewski Matthew L, Curtis Lesley H, Gandhi Mihir, Pietrobon Ricardo, Jacobs Danny O, Ostbye Truls
Incorporation of non-natural amino acids improves cell permeability and potency of specific inhibitors of proteasome trypsin-like sites
Geurink P, Overkleeft H, Groll M, van der Stelt M, Driessen C, van der Marel G, Florea B, Mock E, Voges M, Blom A, de Bruin G, Gallastegui N, Mirabella A, van der Linden W, Kisselev A. Incorporation of non-natural amino acids improves cell permeability and potency of specific inhibitors of proteasome trypsin-like sites. J Med Chem 2013; 56:1262-75.
Jan 28, 2013Incorporation of non-natural amino acids improves cell permeability and potency of specific inhibitors of proteasome trypsin-like sites
Jan 28, 2013J Med Chem 2013; 56:1262-75
Geurink Paul P, Overkleeft Herman S, Groll Michael, van der Stelt Mario, Driessen Christoph, van der Marel Gijs A, Florea Bogdan I, Mock Elliot D, Voges Mathias J, Blom Annet E M, de Bruin Gerjan, Gallastegui Nerea, Mirabella Anne C, van der Linden Wouter A, Kisselev Alexei F
The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
Voskens C, Mateus C, Mohr P, Paetzold S, Satzger I, Schadendorf D, Schlaeppi M, Schuler G, Schuler-Thurner B, Trefzer U, Ulrich J, Vaubel J, von Moos R, Weder P, Wilhelm T, Göppner D, Dummer R, Klein C, Keller U, Goldinger S, Loquai C, Robert C, Kaehler K, Berking C, Bergmann T, Bockmeyer C, Eigentler T, Fluck M, Garbe C, Gutzmer R, Grabbe S, Hauschild A, Hein R, Hundorfean G, Justich A, Heinzerling L. The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network. PloS one 2013; 8:e53745.
Jan 14, 2013The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
Jan 14, 2013PloS one 2013; 8:e53745
Voskens Caroline J, Mateus Christine, Mohr Peter, Paetzold Sylvie, Satzger Imke, Schadendorf Dirk, Schlaeppi Marc, Schuler Gerold, Schuler-Thurner Beatrice, Trefzer Uwe, Ulrich Jens, Vaubel Julia, von Moos Roger, Weder Patrik, Wilhelm Tabea, Göppner Daniela, Dummer Reinhard, Klein Christina, Keller Ullrich, Goldinger Simone M, Loquai Carmen, Robert Caroline, Kaehler Katharina C, Berking Carola, Bergmann Tanja, Bockmeyer Clemens L, Eigentler Thomas, Fluck Michael, Garbe Claus, Gutzmer Ralf, Grabbe Stephan, Hauschild Axel, Hein Rüdiger, Hundorfean Gheorghe, Justich Armin, Heinzerling Lucie M
Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas
Hundsberger T, Brügge D, Putora P, Weder P, Weber J, Plasswilm L. Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas. J Neurooncol 2013; 112:133-9.
Jan 12, 2013Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas
Jan 12, 2013J Neurooncol 2013; 112:133-9
Hundsberger Thomas, Brügge Detlef, Putora Paul Martin, Weder Patrik, Weber Johannes, Plasswilm Ludwig
Nutrition impact symptoms in advanced cancer patients: frequency and specific interventions, a case-control study
Omlin A, Blum D, Wierecky J, Haile S, Ottery F, Strasser F. Nutrition impact symptoms in advanced cancer patients: frequency and specific interventions, a case-control study. J Cachexia Sarcopenia Muscle 2013; 4:55-61.
Jan 11, 2013Nutrition impact symptoms in advanced cancer patients: frequency and specific interventions, a case-control study
Jan 11, 2013J Cachexia Sarcopenia Muscle 2013; 4:55-61
Omlin Aurelius, Blum David, Wierecky Jan, Haile Sarah, Ottery Faith D, Strasser Florian
Angioedema in a patient with renal cell cancer treated with everolimus in combination with an angiotensin-converting enzyme inhibitor
Rothermundt C, Gillessen Sommer S. Angioedema in a patient with renal cell cancer treated with everolimus in combination with an angiotensin-converting enzyme inhibitor. J Clin Oncol 2013; 31:e57-8.
Jan 7, 2013Angioedema in a patient with renal cell cancer treated with everolimus in combination with an angiotensin-converting enzyme inhibitor
Jan 7, 2013J Clin Oncol 2013; 31:e57-8
Rothermundt Christian, Gillessen Sommer Silke
T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein
Laurent J, Gnad-Vogt U, Stupp R, Quaratino S, Sessa C, Omlin A, Beck J, Gallerani E, Liedert B, Ongarello S, Bertrand C, Vicari M, Joffraud M, Gillessen Sommer S, Touvrey C, Speiser D. T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein. J Transl Med 2013; 11:5.
Jan 7, 2013T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein
Jan 7, 2013J Transl Med 2013; 11:5
Laurent Julien, Gnad-Vogt Ulrike S, Stupp Roger, Quaratino Sonia, Sessa Cristiana, Omlin Aurelius, Beck Joachim, Gallerani Elisa, Liedert Bernd, Ongarello Stefano, Bertrand Caroline, Vicari Manuela, Joffraud Magali, Gillessen Sommer Silke, Touvrey Cedric, Speiser Daniel E
Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms
Omlin A, Attard G, Parker C, Thompson E, Maier G, Ferraldeschi R, Olmos D, Bianchini D, Sandhu S, Mulick Cassidy A, Mukherji D, Pezaro C, de Bono J. Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. Eur Urol 2013; 64:300-6.
Jan 4, 2013Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms
Jan 4, 2013Eur Urol 2013; 64:300-6
Omlin Aurelius, Attard Gerhardt, Parker Chris, Thompson Emilda, Maier Gal, Ferraldeschi Roberta, Olmos David, Bianchini Diletta, Sandhu Shahneen, Mulick Cassidy Amy, Mukherji Deborah, Pezaro Carmel, de Bono Johann
Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial
Oakman C, Harvey V, Punzalan L, Dell'orto P, Larsimont D, Steinberg I, Gelber R, Piccart-Gebhart M, Viale G, Gutiérrez J, Thürlimann B, Jakesz R, Francis P, Crown J, Quinaux E, Buyse M, De Azambuja E, Margeli Vila M, Andersson M, Nordenskjöld B, Di Leo A. Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial. Ann Oncol 2013; 24:1203-11.
Jan 4, 2013Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial
Jan 4, 2013Ann Oncol 2013; 24:1203-11
Oakman C, Harvey V, Punzalan L, Dell'orto P, Larsimont D, Steinberg I, Gelber R D, Piccart-Gebhart M, Viale G, Gutiérrez J, Thürlimann Beat, Jakesz R, Francis P A, Crown J, Quinaux E, Buyse M, De Azambuja E, Margeli Vila M, Andersson M, Nordenskjöld B, Di Leo A
Der Mystiker aus Nazaret
Renz M. Der Mystiker aus Nazaret - Jesus neu begegnen - Jesuanische Spiritualität. Freiburg i.Br.: Kreuz, 2013.
Jan 1, 2013Der Mystiker aus Nazaret
Jan 1, 2013Kreuz
Renz Monika